300149 睿智医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)2.070-17.089-48.47716.827-18.316
总资产报酬率 ROA (%)1.277-10.224-29.3729.037-9.647
投入资产回报率 ROIC (%)1.437-11.502-32.93910.070-10.735

边际利润分析
销售毛利率 (%)29.01421.80025.93525.42331.690
营业利润率 (%)5.933-22.350-82.25556.350-21.021
息税前利润/营业总收入 (%)6.188-23.476-81.32255.826-16.483
净利润/营业总收入 (%)4.748-23.347-80.54927.320-23.783

收益指标分析
经营活动净收益/利润总额(%)63.04726.5216.392-11.3152.377
价值变动净收益/利润总额(%)40.106-3.3650.098190.871-3.061
营业外收支净额/利润总额(%)1.3686.3920.362-2.5751.559

偿债能力分析
流动比率 (X)1.9811.8581.7041.7490.694
速动比率 (X)1.9401.8251.6391.6910.625
资产负债率 (%)36.26737.96739.98837.76252.839
带息债务/全部投入资本 (%)10.12210.54610.32915.54431.887
股东权益/带息债务 (%)695.813648.516643.036443.387162.182
股东权益/负债合计 (%)172.366160.194147.585163.12188.150
利息保障倍数 (X)35.919-58.773-66.00862.684-3.384

营运能力分析
应收账款周转天数 (天)60.96181.73895.71891.81476.617
存货周转天数 (天)6.0659.32915.09420.31019.267